SELECTED PULICATIONS

Martínez JL, Lemus N, Lai TY, Mishra M, González-Domínguez I, Puente-Massaguer E, Loganathan M, Francis B, Samanovic MI, Krammer F, Mulligan MJ, Simon V, Palese P, Sun W. The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin increases with high immunoglobulin titers of the cohorts and with young age, but not sex. Vaccine. 2024 Apr 15;. doi: 10.1016/j.vaccine.2024.04.037. [Epub ahead of print] PubMed PMID: 38627145.

Carreño JM, Raskin A, Singh G, Tcheou J, Kawabata H, Gleason C, Srivastava K, Vigdorovich V, Dambrauskas N, Gupta SL, González Domínguez I, Martinez JL, Slamanig S, Sather DN, Raghunandan R, Wirachwong P, Muangnoicharoen S, Pitisuttithum P, Wrammert J, Suthar MS, Sun W, Palese P, García-Sastre A, Simon V, Krammer F. An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination. Sci Transl Med. 2023 Feb 15;15(683):eabo2847. doi: 10.1126/scitranslmed.abo2847. Epub 2023 Feb 15. PubMed PMID: 36791207.

Duty JA, Kraus T, Zhou H, Zhang Y, Shaabani N, Yildiz S, Du N, Singh A, Miorin L, Li D, Stegman K, Ophir S, Cao X, Atanasoff K, Lim R, Mena I, Bouvier NM, Kowdle S, Carreño JM, Rivero-Nava L, Raskin A, Moreno E, Johnson S, Rathnasinghe R, Pai CI, Kehrer T, Cabral EP, Jangra S, Healy L, Singh G, Warang P, Simon V, Sordillo EM, van Bakel H, Liu Y, Sun W, Kerwin L, Teijaro J, Schotsaert M, Krammer F, Bresson D, García-Sastre A, Fu Y, Lee B, Powers C, Moran T, Ji H, Tortorella D, Allen R. Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants. Med. 2022 Oct 14;3(10):705-721.e11. doi: 10.1016/j.medj.2022.08.002. Epub 2022 Aug 8. PubMed PMID: 36044897; PubMed Central PMCID: PMC9359501.

González-Domínguez I, Martínez JL, Slamanig S, Lemus N, Liu Y, Lai TY, Carreño JM, Singh G, Singh G, Schotsaert M, Mena I, McCroskery S, Coughlan L, Krammer F, García-Sastre A, Palese P, Sun W. Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. Microbiol Spectr. 2022 Jun 29;10(3):e0153822. doi: 10.1128/spectrum.01538-22. Epub 2022 Jun 6. PubMed PMID: 35658571; PubMed Central PMCID: PMC9241906.

Duc Dang A, Dinh Vu T, Hai Vu H, Thanh Ta V, Thi Van Pham A, Thi Ngoc Dang M, Van Le B, Huu Duong T, Van Nguyen D, Lawpoolsri S, Chinwangso P, McLellan JS, Hsieh CL, Garcia-Sastre A, Palese P, Sun W, Martinez JL, Gonzalez-Dominguez I, Slamanig S, Manuel Carreño J, Tcheou J, Krammer F, Raskin A, Minh Vu H, Cong Tran T, Mai Nguyen H, Mercer LD, Raghunandan R, Lal M, White JA, Hjorth R, Innis BL, Scharf R. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. Vaccine. 2022 Jun 9;40(26):3621-3632. doi: 10.1016/j.vaccine.2022.04.078. Epub 2022 May 14. PubMed PMID: 35577631; PubMed Central PMCID: PMC9106407.

Zhu X, Han J, Sun W, Puente-Massaguer E, Yu W, Palese P, Krammer F, Ward AB, Wilson IA. Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface. Proc Natl Acad Sci U S A. 2022 May 24;119(21):e2200821119. doi: 10.1073/pnas.2200821119. Epub 2022 May 20. PubMed PMID: 35594401; PubMed Central PMCID: PMC9173763.

Bliss CM, Freyn AW, Caniels TG, Leyva-Grado VH, Nachbagauer R, Sun W, Tan GS, Gillespie VL, McMahon M, Krammer F, Hill AVS, Palese P, Coughlan L. A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice. Mol Ther. 2022 May 4;30(5):2024-2047. doi: 10.1016/j.ymthe.2022.01.011. Epub 2022 Jan 7. PubMed PMID: 34999208; PubMed Central PMCID: PMC9092311.

Pitisuttithum P, Luvira V, Lawpoolsri S, Muangnoicharoen S, Kamolratanakul S, Sivakorn C, Narakorn P, Surichan S, Prangpratanporn S, Puksuriwong S, Lamola S, Mercer LD, Raghunandan R, Sun W, Liu Y, Carreño JM, Scharf R, Phumratanaprapin W, Amanat F, Gagnon L, Hsieh CL, Kaweepornpoj R, Khan S, Lal M, McCroskery S, McLellan J, Mena I, Meseck M, Phonrat B, Sabmee Y, Singchareon R, Slamanig S, Suthepakul N, Tcheou J, Thantamnu N, Theerasurakarn S, Tran S, Vilasmongkolchai T, White JA, Bhardwaj N, Garcia-Sastre A, Palese P, Krammer F, Poopipatpol K, Wirachwong P, Hjorth R, Innis BL. Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. EClinicalMedicine. 2022 Mar;45:101323. doi: 10.1016/j.eclinm.2022.101323. eCollection 2022 Mar. PubMed PMID: 35284808; PubMed Central PMCID: PMC8903824.

Tcheou J, Raskin A, Singh G, Kawabata H, Bielak D, Sun W, González-Domínguez I, Sather DN, García-Sastre A, Palese P, Krammer F, Carreño JM. Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats. Front Immunol. 2021;12:791764. doi: 10.3389/fimmu.2021.791764. eCollection 2021. PubMed PMID: 34868082; PubMed Central PMCID: PMC8637447.

Sun W, Liu Y, Amanat F, González-Domínguez I, McCroskery S, Slamanig S, Coughlan L, Rosado V, Lemus N, Jangra S, Rathnasinghe R, Schotsaert M, Martinez JL, Sano K, Mena I, Innis BL, Wirachwong P, Thai DH, Oliveira RDN, Scharf R, Hjorth R, Raghunandan R, Krammer F, García-Sastre A, Palese P. A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nat Commun. 2021 Oct 27;12(1):6197. doi: 10.1038/s41467-021-26499-y. PubMed PMID: 34707161; PubMed Central PMCID: PMC8551302.

Lara-Puente JH, Carreño JM, Sun W, Suárez-Martínez A, Ramírez-Martínez L, Quezada-Monroy F, Paz-De la Rosa G, Vigueras-Moreno R, Singh G, Rojas-Martínez O, Chagoya-Cortés HE, Sarfati-Mizrahi D, Soto-Priante E, López-Macías C, Krammer F, Castro-Peralta F, Palese P, García-Sastre A, Lozano-Dubernard B. Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs. mBio. 2021 Oct 26;12(5):e0190821. doi: 10.1128/mBio.01908-21. Epub 2021 Sep 21. PubMed PMID: 34544278; PubMed Central PMCID: PMC8546847.

Pitisuttithum P, Luvira V, Lawpoolsri S, Muangnoicharoen S, Kamolratanakul S, Sivakorn C, Narakorn P, Surichan S, Prangpratanporn S, Puksuriwong S, Lamola S, Mercer LD, Raghunandan R, Sun W, Liu Y, Carreño JM, Scharf R, Phumratanaprapin W, Amanat F, Gagnon L, Hsieh CL, Kaweepornpoj R, Khan S, Lal M, McCroskery S, McLellan J, Mena I, Meseck M, Phonrat B, Sabmee Y, Singchareon R, Slamanig S, Suthepakul N, Tcheou J, Thantamnu N, Theerasurakarn S, Tran S, Vilasmongkolchai T, White JA, Garcia-Sastre A, Palese P, Krammer F, Poopipatpol K, Wirachwong P, Hjorth R, Innis BL. Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial. medRxiv. 2021 Sep 22;. doi: 10.1101/2021.09.17.21263758. PubMed PMID: 34580673; PubMed Central PMCID: PMC8475960.

Liu Y, Strohmeier S, González-Domínguez I, Tan J, Simon V, Krammer F, García-Sastre A, Palese P, Sun W. Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice. Front Immunol. 2021;12:746447. doi: 10.3389/fimmu.2021.746447. eCollection 2021. PubMed PMID: 34603333; PubMed Central PMCID: PMC8481571.

Guthmiller JJ, Utset HA, Henry C, Li L, Zheng NY, Sun W, Costa Vieira M, Zost S, Huang M, Hensley SE, Cobey S, Palese P, Wilson PC. An Egg-Derived Sulfated N-Acetyllactosamine Glycan Is an Antigenic Decoy of Influenza Virus Vaccines. mBio. 2021 Jun 29;12(3):e0083821. doi: 10.1128/mBio.00838-21. Epub 2021 Jun 15. PubMed PMID: 34126773; PubMed Central PMCID: PMC8263001.

Wong PT, Goff PH, Sun RJ, Ruge MJ, Ermler ME, Sebring A, O’Konek JJ, Landers JJ, Janczak KW, Sun W, Baker JR Jr. Combined Intranasal Nanoemulsion and RIG-I Activating RNA Adjuvants Enhance Mucosal, Humoral, and Cellular Immunity to Influenza Virus. Mol Pharm. 2021 Feb 1;18(2):679-698. doi: 10.1021/acs.molpharmaceut.0c00315. Epub 2020 Jun 15. PubMed PMID: 32491861.

Nachbagauer R, Feser J, Naficy A, Bernstein DI, Guptill J, Walter EB, Berlanda-Scorza F, Stadlbauer D, Wilson PC, Aydillo T, Behzadi MA, Bhavsar D, Bliss C, Capuano C, Carreño JM, Chromikova V, Claeys C, Coughlan L, Freyn AW, Gast C, Javier A, Jiang K, Mariottini C, McMahon M, McNeal M, Solórzano A, Strohmeier S, Sun W, Van der Wielen M, Innis BL, García-Sastre A, Palese P, Krammer F. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat Med. 2021 Jan;27(1):106-114. doi: 10.1038/s41591-020-1118-7. Epub 2020 Dec 7. PubMed PMID: 33288923.

Sun W, McCroskery S, Liu WC, Leist SR, Liu Y, Albrecht RA, Slamanig S, Oliva J, Amanat F, Schäfer A, Dinnon KH 3rd, Innis BL, García-Sastre A, Krammer F, Baric RS, Palese P. A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines (Basel). 2020 Dec 17;8(4). doi: 10.3390/vaccines8040771. PubMed PMID: 33348607; PubMed Central PMCID: PMC7766959.

Sun W, Leist SR, McCroskery S, Liu Y, Slamanig S, Oliva J, Amanat F, Schäfer A, Dinnon KH 3rd, García-Sastre A, Krammer F, Baric RS, Palese P. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine. 2020 Dec;62:103132. doi: 10.1016/j.ebiom.2020.103132. Epub 2020 Nov 21. PubMed PMID: 33232870; PubMed Central PMCID: PMC7679520.

Sun W, McCroskery S, Liu WC, Leist SR, Liu Y, Albrecht RA, Slamanig S, Oliva J, Amanat F, Schaefer A, Dinnon KH, Innis BL, Garcia-Sastre A, Krammer F, Baric RS, Palese P. A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine. bioRxiv. 2020 Jul 31;. doi: 10.1101/2020.07.30.229120. PubMed PMID: 32766572; PubMed Central PMCID: PMC7402029.

Zheng A, Sun W, Xiong X, Freyn AW, Peukes J, Strohmeier S, Nachbagauer R, Briggs JAG, Krammer F, Palese P. Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals. J Virol. 2020 Jul 30;94(16). doi: 10.1128/JVI.00742-20. Print 2020 Jul 30. PubMed PMID: 32493826; PubMed Central PMCID: PMC7394900.

Bernstein DI, Guptill J, Naficy A, Nachbagauer R, Berlanda-Scorza F, Feser J, Wilson PC, Solórzano A, Van der Wielen M, Walter EB, Albrecht RA, Buschle KN, Chen YQ, Claeys C, Dickey M, Dugan HL, Ermler ME, Freeman D, Gao M, Gast C, Guthmiller JJ, Hai R, Henry C, Lan LY, McNeal M, Palm AE, Shaw DG, Stamper CT, Sun W, Sutton V, Tepora ME, Wahid R, Wenzel H, Wohlbold TJ, Innis BL, García-Sastre A, Palese P, Krammer F. Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. Lancet Infect Dis. 2020 Jan;20(1):80-91. doi: 10.1016/S1473-3099(19)30393-7. Epub 2019 Oct 17. PubMed PMID: 31630990; PubMed Central PMCID: PMC6928577.

Nachbagauer R, Salaun B, Stadlbauer D, Behzadi MA, Friel D, Rajabhathor A, Choi A, Albrecht RA, Debois M, García-Sastre A, Rouxel RN, Sun W, Palese P, Mallett CP, Innis BL, Krammer F, Claeys C. Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts. NPJ Vaccines. 2019;4:51. doi: 10.1038/s41541-019-0147-z. eCollection 2019. PubMed PMID: 31839997; PubMed Central PMCID: PMC6898674.

Sun W, Zheng A, Miller R, Krammer F, Palese P. An Inactivated Influenza Virus Vaccine Approach to Targeting the Conserved Hemagglutinin Stalk and M2e Domains. Vaccines (Basel). 2019 Sep 18;7(3). doi: 10.3390/vaccines7030117. PubMed PMID: 31540436; PubMed Central PMCID: PMC6789539.

Broecker F, Zheng A, Suntronwong N, Sun W, Bailey MJ, Krammer F, Palese P. Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase. J Virol. 2019 Sep 15;93(18). doi: 10.1128/JVI.00840-19. Print 2019 Sep 15. PubMed PMID: 31375573; PubMed Central PMCID: PMC6714795.

Broecker F, Liu STH, Suntronwong N, Sun W, Bailey MJ, Nachbagauer R, Krammer F, Palese P. A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains. NPJ Vaccines. 2019;4:31. doi: 10.1038/s41541-019-0126-4. eCollection 2019. PubMed PMID: 31341648; PubMed Central PMCID: PMC6642189.

Sun W, Kirkpatrick E, Ermler M, Nachbagauer R, Broecker F, Krammer F, Palese P. Development of Influenza B Universal Vaccine Candidates Using the “Mosaic” Hemagglutinin Approach. J Virol. 2019 Jun 15;93(12). doi: 10.1128/JVI.00333-19. Print 2019 Jun 15. PubMed PMID: 30944178; PubMed Central PMCID: PMC6613766.

Sun W, Kang DS, Zheng A, Liu STH, Broecker F, Simon V, Krammer F, Palese P. Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans. J Virol. 2019 Jan 15;93(2). doi: 10.1128/JVI.01673-18. Print 2019 Jan 15. PubMed PMID: 30381487; PubMed Central PMCID: PMC6321909.

Liu STH, Behzadi MA, Sun W, Freyn AW, Liu WC, Broecker F, Albrecht RA, Bouvier NM, Simon V, Nachbagauer R, Krammer F, Palese P. Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance. J Clin Invest. 2018 Nov 1;128(11):4992-4996. doi: 10.1172/JCI122895. Epub 2018 Oct 8. PubMed PMID: 30188868; PubMed Central PMCID: PMC6205383.

Broecker F, Liu STH, Sun W, Krammer F, Simon V, Palese P. Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice. J Virol. 2018 Oct 15;92(20). doi: 10.1128/JVI.01100-18. Print 2018 Oct 15. PubMed PMID: 30045991; PubMed Central PMCID: PMC6158429.

Fulton BO, Sun W, Heaton NS, Palese P. The Influenza B Virus Hemagglutinin Head Domain Is Less Tolerant to Transposon Mutagenesis than That of the Influenza A Virus. J Virol. 2018 Aug 15;92(16). doi: 10.1128/JVI.00754-18. Print 2018 Aug 15. PubMed PMID: 29899093; PubMed Central PMCID: PMC6069205.

Rajendran M, Sun W, Comella P, Nachbagauer R, Wohlbold TJ, Amanat F, Kirkpatrick E, Palese P, Krammer F. An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations. PLoS One. 2018;13(4):e0194830. doi: 10.1371/journal.pone.0194830. eCollection 2018. PubMed PMID: 29617394; PubMed Central PMCID: PMC5884525.

Cifuentes-Muñoz N, Sun W, Ray G, Schmitt PT, Webb S, Gibson K, Dutch RE, Schmitt AP. Mutations in the Transmembrane Domain and Cytoplasmic Tail of Hendra Virus Fusion Protein Disrupt Virus-Like-Particle Assembly. J Virol. 2017 Jul 15;91(14). doi: 10.1128/JVI.00152-17. Print 2017 Jul 15. PubMed PMID: 28468881; PubMed Central PMCID: PMC5487568.

Ermler ME, Kirkpatrick E, Sun W, Hai R, Amanat F, Chromikova V, Palese P, Krammer F. Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model. J Virol. 2017 Jun 15;91(12). doi: 10.1128/JVI.00286-17. Print 2017 Jun 15. PubMed PMID: 28356526; PubMed Central PMCID: PMC5446656.

Sun W, McCrory TS, Khaw WY, Petzing S, Myers T, Schmitt AP. Matrix proteins of Nipah and Hendra viruses interact with beta subunits of AP-3 complexes. J Virol. 2014 Nov;88(22):13099-110. doi: 10.1128/JVI.02103-14. Epub 2014 Sep 10. PubMed PMID: 25210190; PubMed Central PMCID: PMC4249102.